AT4 receptor ligands as angiogenic, anti-angiogenic, and anti-tumor agents
AssigneesPacific Northwest Biotechnology Inc., Washington State University Research Foundation
InventorsJoseph W Harding, John W Wright
Life of this patent
Estimating the term…
Abstract
AT4 receptor agonists are potent activators of angiogenesis and can be used to treat diseases that are characterized by vascular insufficiency. AT4 receptor antagonists, which are potent inhibitors of angiogenesis, and can be used as anti-angiogenic agents for the treatment of cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerotic plaque formation, and any disease process that is characterized by excessive, undesired or inappropriate angiogenesis or proliferation of endothelial cells.
Claims24
A method of inhibiting angiogenesis in pathological conditions where increased angiogenesis and coincidental vascular perfusion are clinically detrimental, comprising the steps of:
- producing an AT4 receptor ligand, having a structure selected form the group consisting of NH3+-norleucine-tyrosine-isoleucine-histidine-COO−(SEQ ID NO:
- 4), and norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-CONH2SEQ ID NO:
- 1);
- and administering the AT4 receptor ligand.
A method of inihibiting angiogenesis in pathological conditions where increased angiogenesis and coincidental vascular perfusion are clinically detrimental, comprising the steps of:
- producing an AT4 receptor ligand having a structure of:
- norleucine-tyrosine-lucine-Ψ-(CH2-NH2)3-4-histidine-proline-phenylalanine-COO−(SEQ ID NO 3;
- and administering the AT4 receptor ligand.
A method of inhibiting the growth and metastasis of solid tumors, comprising the steps of:
- producing an AT4 receptor ligand, having a structure selected from the group consisting of:
- NH3+-norleucine-tyrosine-isoleucine-histidine-COO−(SEQ ID NO:
- 4), and norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-CONH2(SEQ ID NO:
- 1);
- and administering the AT4 receptor ligand.
A method of inhibiting the growth and metastasis of solid tumors, comprising the steps of:
- producing an AT4 receptor ligand having a structure of:
- norleucine-tyrosine-leucine-Ψ-(CH2-NH2)3-4-histidine-proline-phenylalanine-COO−(SEQ ID NO:
- 3;
- and administering the AT4 receptor ligand.
A method of inhibiting the growth and metastasis of breast cancer, comprising the steps of:
- producing an AT4 receptor ligand, having a structure selected from the group consisting of:
- NH3+-norleucine-tyrosine-isoleucine-histidine-COO−(SEQ ID NO:
- 4), and norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-CONH2(SEQ ID NO:
- 1);
- and administering the AT4 receptor ligand.
A method of inhibiting the growth and metastasis of breast cancer, comprising the steps of:
- producing an AT4 receptor ligand having a structure of:
- norleucine-tyrosine-leucine-Ψ-(CH2-NH2)3-4-histidine-proline-phenylalanine-COO−(SEQ ID NO:
- 3);
- and administering the AT4 receptor ligand.
Dependencies are inferred from the claim text.